JP2007520540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520540A5 JP2007520540A5 JP2006551923A JP2006551923A JP2007520540A5 JP 2007520540 A5 JP2007520540 A5 JP 2007520540A5 JP 2006551923 A JP2006551923 A JP 2006551923A JP 2006551923 A JP2006551923 A JP 2006551923A JP 2007520540 A5 JP2007520540 A5 JP 2007520540A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidin
- thiazol
- chloro
- compound
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 12
- -1 4-methylthiazol-2-yl Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108090000433 Aurora kinases Proteins 0.000 claims 2
- 102000003989 Aurora kinases Human genes 0.000 claims 2
- 108091007911 GSKs Proteins 0.000 claims 2
- 102000038624 GSKs Human genes 0.000 claims 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- ZYAAOFFRIZSHKG-UHFFFAOYSA-N ethyl 2-[2-(4-chloroanilino)pyrimidin-4-yl]-4-hydroxy-1,3-thiazole-5-carboxylate Chemical compound OC1=C(C(=O)OCC)SC(C=2N=C(NC=3C=CC(Cl)=CC=3)N=CC=2)=N1 ZYAAOFFRIZSHKG-UHFFFAOYSA-N 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- DFKBWWLQZWPHAU-UHFFFAOYSA-N n-(6-methoxypyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1=NC(OC)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 DFKBWWLQZWPHAU-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- AMEYMCDOKAYHNU-UHFFFAOYSA-N 2-[2-[(6-chloropyridin-3-yl)amino]pyrimidin-4-yl]-5-methyl-1,3-thiazol-4-ol Chemical compound OC1=C(C)SC(C=2N=C(NC=3C=NC(Cl)=CC=3)N=CC=2)=N1 AMEYMCDOKAYHNU-UHFFFAOYSA-N 0.000 claims 1
- LPMPZSLQZGKCCU-UHFFFAOYSA-N 3-n-[4-(4,5-dimethyl-1,3-thiazol-2-yl)pyrimidin-2-yl]benzene-1,3-diamine Chemical compound S1C(C)=C(C)N=C1C1=CC=NC(NC=2C=C(N)C=CC=2)=N1 LPMPZSLQZGKCCU-UHFFFAOYSA-N 0.000 claims 1
- FEQQALGLKRLIPK-UHFFFAOYSA-N 4-(4,5-dimethyl-1,3-thiazol-2-yl)-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C=2SC(C)=C(C)N=2)=C1 FEQQALGLKRLIPK-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- HOPVZZZPBBETCV-UHFFFAOYSA-N C(C)OC(=O)C1=C(N=C(S1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C1=CC=CC=C1 Chemical compound C(C)OC(=O)C1=C(N=C(S1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C1=CC=CC=C1 HOPVZZZPBBETCV-UHFFFAOYSA-N 0.000 claims 1
- FTQIYEJGQVOMJL-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)N1CCOCC1.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C FTQIYEJGQVOMJL-UHFFFAOYSA-N 0.000 claims 1
- CHEHWXHOTMAJOR-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)O.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=C(C=C1)C)[N+](=O)[O-] Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC=C(C=C1)O.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=C(C=C1)C)[N+](=O)[O-] CHEHWXHOTMAJOR-UHFFFAOYSA-N 0.000 claims 1
- GTYAEYNUFDCEFV-UHFFFAOYSA-N CC=1N=C(SC1C)C1=NC(=NC=C1)NC=1C=NC(=CC1)OC.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O Chemical compound CC=1N=C(SC1C)C1=NC(=NC=C1)NC=1C=NC(=CC1)OC.ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O GTYAEYNUFDCEFV-UHFFFAOYSA-N 0.000 claims 1
- UMQAAJLCTFZUGO-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)O)C(=O)O.COC(CC=1N=C(SC1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)=O Chemical compound ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)O)C(=O)O.COC(CC=1N=C(SC1)C1=NC(=NC=C1)NC1=CC=C(C=C1)Cl)=O UMQAAJLCTFZUGO-UHFFFAOYSA-N 0.000 claims 1
- QZSNMAAZRPQZGJ-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O Chemical compound ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC=C(N1)C.ClC1=CC=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C(C)=O QZSNMAAZRPQZGJ-UHFFFAOYSA-N 0.000 claims 1
- DRFUEMRXRKKVTE-UHFFFAOYSA-N ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.COC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1 Chemical compound ClC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.COC1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1 DRFUEMRXRKKVTE-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 102000001267 GSK3 Human genes 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- AFOGVURHRPHMFJ-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4,5-dimethyl-1,3-thiazol-2-yl)pyrimidin-2-amine 4-(4,5-dimethyl-1,3-thiazol-2-yl)-N-[3-(trifluoromethyl)phenyl]pyrimidin-2-amine Chemical compound ClC1=C(C=C(C=C1)NC1=NC=CC(=N1)C=1SC(=C(N1)C)C)C(F)(F)F.CC=1N=C(SC1C)C1=NC(=NC=C1)NC1=CC(=CC=C1)C(F)(F)F AFOGVURHRPHMFJ-UHFFFAOYSA-N 0.000 claims 1
- DUILLRPTPDOWDS-UHFFFAOYSA-N N1(CCCC1)C1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.ClC1=CC=C(C=C1)NC1=NC=CC(=C1)C=1SC(=C(N1)O)C Chemical compound N1(CCCC1)C1=CC=C(C=N1)NC1=NC=CC(=N1)C=1SC=CN1.ClC1=CC=C(C=C1)NC1=NC=CC(=C1)C=1SC(=C(N1)O)C DUILLRPTPDOWDS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- ZULPZVQQKCPAAS-UHFFFAOYSA-N n-(6-chloro-5-methylpyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound N1=C(Cl)C(C)=CC(NC=2N=C(C=CN=2)C=2SC=CN=2)=C1 ZULPZVQQKCPAAS-UHFFFAOYSA-N 0.000 claims 1
- LNTKBKLVTCCBCH-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1=NC(Cl)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 LNTKBKLVTCCBCH-UHFFFAOYSA-N 0.000 claims 1
- BWPWWOIILUWVKU-UHFFFAOYSA-N n-(6-pyrrolidin-1-ylpyridin-3-yl)-4-(1,3-thiazol-2-yl)pyrimidin-2-amine Chemical compound C1CCCN1C(N=C1)=CC=C1NC1=NC=CC(C=2SC=CN=2)=N1 BWPWWOIILUWVKU-UHFFFAOYSA-N 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402653.0A GB0402653D0 (en) | 2004-02-06 | 2004-02-06 | Compounds |
| PCT/GB2005/000405 WO2005075468A2 (en) | 2004-02-06 | 2005-02-07 | Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520540A JP2007520540A (ja) | 2007-07-26 |
| JP2007520540A5 true JP2007520540A5 (https=) | 2008-02-28 |
Family
ID=31985793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551923A Pending JP2007520540A (ja) | 2004-02-06 | 2005-02-07 | 化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080318954A1 (https=) |
| EP (1) | EP1751146B1 (https=) |
| JP (1) | JP2007520540A (https=) |
| CN (1) | CN1914199A (https=) |
| AT (1) | ATE450532T1 (https=) |
| AU (1) | AU2005210254A1 (https=) |
| BR (1) | BRPI0507506A (https=) |
| CA (1) | CA2554329A1 (https=) |
| DE (1) | DE602005018044D1 (https=) |
| GB (1) | GB0402653D0 (https=) |
| IL (1) | IL177252A0 (https=) |
| WO (1) | WO2005075468A2 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| WO2005012294A1 (en) | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| BRPI0610876B8 (pt) | 2005-06-08 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| MX2008005814A (es) * | 2005-11-03 | 2008-10-15 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| BRPI0808789A2 (pt) * | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
| TW200920355A (en) | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
| HUE030912T2 (en) | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| US8536185B2 (en) * | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| US20110112158A1 (en) | 2009-11-11 | 2011-05-12 | David Robert Bolin | Benzisoxazole analogs as glycogen synthase activators |
| US20110112147A1 (en) | 2009-11-11 | 2011-05-12 | David Robert Bolin | Indazolone analogs as glycogen synthase activators |
| US7947728B1 (en) | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
| US8039495B2 (en) | 2009-11-16 | 2011-10-18 | Hoffman-La Roche Inc. | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators |
| US20110118314A1 (en) | 2009-11-16 | 2011-05-19 | Weiya Yun | Piperidine analogs as glycogen synthase activators |
| US7939569B1 (en) | 2009-12-01 | 2011-05-10 | Hoffmann-La Roche Inc. | Aniline analogs as glycogen synthase activators |
| US20110136792A1 (en) | 2009-12-04 | 2011-06-09 | David Robert Bolin | Novel carboxylic acid analogs as glycogen synthase activators |
| ES2577829T3 (es) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| NO2638031T3 (https=) | 2010-11-10 | 2018-03-10 | ||
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| EP2802576B1 (en) | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| BR112015009850A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| US10053455B2 (en) | 2014-03-24 | 2018-08-21 | Ab Science | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| EP3313840B1 (en) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| US10618903B2 (en) | 2015-06-24 | 2020-04-14 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| USRE49850E1 (en) * | 2015-08-04 | 2024-02-27 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| EP3144307A1 (en) | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
| PT3621960T (pt) | 2017-05-11 | 2021-09-16 | Bristol Myers Squibb Co | Tienopiridinas e benzotiofenos úteis como inibidores de irak4 |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| EP3999508B1 (en) | 2019-07-18 | 2023-08-30 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021011727A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS |
| US12304916B2 (en) | 2019-07-23 | 2025-05-20 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors |
| WO2021026181A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| ES3059914T3 (en) | 2019-08-13 | 2026-03-24 | Bristol Myers Squibb Co | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| US12421230B2 (en) | 2020-02-03 | 2025-09-23 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors |
| KR20220161396A (ko) * | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
| GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69736351D1 (de) * | 1996-05-08 | 2006-08-31 | Cyclacel Ltd | Methoden und mittel zur hemmung der cdk4-aktivität |
| US6703395B2 (en) * | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| AU753015B2 (en) * | 1998-03-04 | 2002-10-03 | Cyclacel Limited | Cyclin dependent kinase inhibitor |
| WO1999065897A1 (en) * | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| CN100355751C (zh) * | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 |
| GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| ES2274035T3 (es) * | 2001-06-01 | 2007-05-16 | Vertex Pharmaceuticals Incorporated | Compuestos de tiazol utiles como inhibidores de proteina quinasas. |
| CN100500663C (zh) * | 2001-09-28 | 2009-06-17 | 西克拉塞尔有限公司 | 作为抗增殖化合物的n-(4-(4-甲基噻唑-5-基)嘧啶-2-基)-n-苯胺 |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| JP2006522125A (ja) * | 2003-03-25 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| JP5164380B2 (ja) * | 2003-10-21 | 2013-03-21 | サイクラセル リミテッド | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
-
2004
- 2004-02-06 GB GBGB0402653.0A patent/GB0402653D0/en not_active Ceased
-
2005
- 2005-02-07 JP JP2006551923A patent/JP2007520540A/ja active Pending
- 2005-02-07 WO PCT/GB2005/000405 patent/WO2005075468A2/en not_active Ceased
- 2005-02-07 BR BRPI0507506-8A patent/BRPI0507506A/pt not_active IP Right Cessation
- 2005-02-07 AU AU2005210254A patent/AU2005210254A1/en not_active Abandoned
- 2005-02-07 AT AT05702134T patent/ATE450532T1/de not_active IP Right Cessation
- 2005-02-07 DE DE602005018044T patent/DE602005018044D1/de not_active Expired - Fee Related
- 2005-02-07 EP EP05702134A patent/EP1751146B1/en not_active Expired - Lifetime
- 2005-02-07 CN CNA2005800039602A patent/CN1914199A/zh active Pending
- 2005-02-07 US US10/588,372 patent/US20080318954A1/en not_active Abandoned
- 2005-02-07 CA CA002554329A patent/CA2554329A1/en not_active Abandoned
-
2006
- 2006-08-02 IL IL177252A patent/IL177252A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520540A5 (https=) | ||
| JP2007509117A5 (https=) | ||
| JP2008500320A5 (https=) | ||
| US20070021419A1 (en) | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
| US10590094B2 (en) | Aminothiazole derivatives useful as antiviral agents | |
| US7902361B2 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| US8329916B2 (en) | Human protein tyrosine phosphatase inhibitors and method of use | |
| US11278534B2 (en) | Enantiomers of substituted thiazoles as antiviral compounds | |
| DE60217140T2 (de) | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen | |
| CN102143953B (zh) | 嘧啶、三嗪类化合物以及它们作为药剂的用途 | |
| RU2469036C2 (ru) | Имидазопиридиновые ингибиторы киназ | |
| US20050288307A1 (en) | Anti-viral compounds | |
| US20090137572A1 (en) | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
| JP2011526616A5 (https=) | ||
| US20030208067A1 (en) | Inhibitors of protein kinase for the treatment of disease | |
| JP2004515550A5 (https=) | ||
| JP2008526824A5 (https=) | ||
| JP2014528450A5 (https=) | ||
| US20050192300A1 (en) | Pyrimidine compounds | |
| EP1648887A1 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| CA2450934A1 (en) | Pyrimidine inhibitors of phosphodiesterase (pde) 7 | |
| CN1592743A (zh) | 糖元合成酶激酶3的抑制剂 | |
| CN1395566A (zh) | 促肾上腺皮质激素释放因子拮抗剂 | |
| JP2009525978A5 (https=) | ||
| CN1656073A (zh) | 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物 |